Next Article in Journal
Therapeutic Efficacy of Silymarin, Vitamin E, and Essential Phospholipid Combination Therapy on Hepatic Steatosis, Fibrosis, and Metabolic Parameters in MASLD Patients: A Prospective Clinical Study
Previous Article in Journal
Purification of Prudu6 from Almond and Its Cross-Reactivity with Glym6 from Soybean
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 26
Issue 12
10.3390/ijms26125426
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Int. J. Mol. Sci. 2014, 15(12), 21913-21934.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Wang et al. The Inhibition of RANKL-Induced Osteoclastogenesis through the Suppression of p38 Signaling Pathway by Naringenin and Attenuation of Titanium-Particle-Induced Osteolysis. Int. J. Mol. Sci. 2014, 15, 21913–21934

by
Wengang Wang
1,†,
Chuanlong Wu
1,†,
Bo Tian
1,†,
Xuqiang Liu
1,
Zanjing Zhai
1,
Xinhua Qu
1,
Chuan Jiang
1,
Zhengxiao Ouyang
1,2,
Yuanqing Mao
1,
Tingting Tang
1,
An Qin
1,* and
Zhenan Zhu
1,*
1
Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedics, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
2
Department of Orthopedics, Hunan Provincial Tumor Hospital and Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2025, 26(12), 5426; https://doi.org/10.3390/ijms26125426
Submission received: 22 March 2025 / Accepted: 19 May 2025 / Published: 6 June 2025
(This article belongs to the Section Biochemistry)
Browse Figures
Versions Notes
In the original publication [1], there was an error in Figures 6B, 7A, 8A and 10A as published. The authors sincerely apologize for this oversight and have confirmed that these errors resulted from the inadvertent use of images. The corrected versions of Figure 6, Figure 7, Figure 8 and Figure 10 are provided below.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Wang, W.; Wu, C.; Tian, B.; Liu, X.; Zhai, Z.; Qu, X.; Jiang, C.; Ouyang, Z.; Mao, Y.; Tang, T.; et al. The Inhibition of RANKL-Induced Osteoclastogenesis through the Suppression of p38 Signaling Pathway by Naringenin and Attenuation of Titanium-Particle-Induced Osteolysis. Int. J. Mol. Sci. 2014, 15, 21913–21934. [Google Scholar] [CrossRef] [PubMed]
Ijms 26 05426 g006
Figure 6. Naringenin (NAR)-mediated suppression of receptor activator of the nuclear factor-κB ligand (RANKL)-induced effects on p38 signaling. (A) p38 phosphorylation was increased within 20–60 min of stimulation with RANKL in the control group and greatly reduced by treatment with 200 μM NAR. MAPK kinase 6 (MKK6) was not affected by 200 μM NAR. (B) Anisomycin (ANI) counteracted the inhibitory effect of NAR on osteoclast formation. BMMs were stimulated with 30 ng/mL macrophage colony-stimulating factor (M-CSF), 50 ng/mL RANKL, and the indicated concentrations of NAR. In the rescue groups, cells were also treated with 2.5 ng/mL anisomycin. All treated cells were stained for tartrate-resistant acid phosphatase (TRAP). (C) The gray levels corresponding to p38 phosphorylation were quantified and normalized relative to β-actin by using ImageJ software Version 1.46, and the results presented in this graph confirmed the data presented in (A). (D) The number of TRAP-positive cells. (E) The area occupied by TRAP-positive cells. * p < 0.05; ** p < 0.01.
Figure 6. Naringenin (NAR)-mediated suppression of receptor activator of the nuclear factor-κB ligand (RANKL)-induced effects on p38 signaling. (A) p38 phosphorylation was increased within 20–60 min of stimulation with RANKL in the control group and greatly reduced by treatment with 200 μM NAR. MAPK kinase 6 (MKK6) was not affected by 200 μM NAR. (B) Anisomycin (ANI) counteracted the inhibitory effect of NAR on osteoclast formation. BMMs were stimulated with 30 ng/mL macrophage colony-stimulating factor (M-CSF), 50 ng/mL RANKL, and the indicated concentrations of NAR. In the rescue groups, cells were also treated with 2.5 ng/mL anisomycin. All treated cells were stained for tartrate-resistant acid phosphatase (TRAP). (C) The gray levels corresponding to p38 phosphorylation were quantified and normalized relative to β-actin by using ImageJ software Version 1.46, and the results presented in this graph confirmed the data presented in (A). (D) The number of TRAP-positive cells. (E) The area occupied by TRAP-positive cells. * p < 0.05; ** p < 0.01.
Ijms 26 05426 g006
Ijms 26 05426 g007
Figure 7. Naringenin (NAR)-mediated effects on receptor activator of the nuclear factor-κB ligand RANKL-induced nuclear factor κB (NF-κB), c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK) signaling. (A) The levels of p-IκBα, IκBα, p-JNK and p-ERK were unaffected by exposure to 200 μM NAR. (B) Luciferase reporter assays showed that NAR did not affect RANKL-induced NF-κB signaling.
Figure 7. Naringenin (NAR)-mediated effects on receptor activator of the nuclear factor-κB ligand RANKL-induced nuclear factor κB (NF-κB), c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK) signaling. (A) The levels of p-IκBα, IκBα, p-JNK and p-ERK were unaffected by exposure to 200 μM NAR. (B) Luciferase reporter assays showed that NAR did not affect RANKL-induced NF-κB signaling.
Ijms 26 05426 g007
Ijms 26 05426 g008
Figure 8. Naringenin (NAR)-mediated suppression of receptor activator of the nuclear factor-κB ligand (RANKL)-induced nuclear factor of activated T cells c1 (NFATc1) signaling. (A) Suppression of RANKL-induced NFATc1 signaling by NAR (200 μM). (B) Quantitative analysis of NFATc1 expression. (C) Levels of the indicated NFATc1 mRNAs following exposure to NAR (0, 25 or 50 μM). (D) Levels of the indicated NFATc1 mRNAs following exposure to 50 μM NAR for 0, 1, 3 or 5 days. * p < 0.05; ** p < 0.01.
Figure 8. Naringenin (NAR)-mediated suppression of receptor activator of the nuclear factor-κB ligand (RANKL)-induced nuclear factor of activated T cells c1 (NFATc1) signaling. (A) Suppression of RANKL-induced NFATc1 signaling by NAR (200 μM). (B) Quantitative analysis of NFATc1 expression. (C) Levels of the indicated NFATc1 mRNAs following exposure to NAR (0, 25 or 50 μM). (D) Levels of the indicated NFATc1 mRNAs following exposure to 50 μM NAR for 0, 1, 3 or 5 days. * p < 0.05; ** p < 0.01.
Ijms 26 05426 g008
Ijms 26 05426 g010
Figure 10. Histological and histomorphometric analysis of the effects of naringenin (NAR) on titanium (Ti) particle-induced mouse calvarial osteolysis. (A) Representative histological sections stained with hematoxylin and eosin (H&E) and stained for tartrate-resistant acid phosphatase (TRAP). (B) Histomorphometric analysis of the number of TRAP-positive multinucleated osteoclasts in the sections. ** p < 0.01.
Figure 10. Histological and histomorphometric analysis of the effects of naringenin (NAR) on titanium (Ti) particle-induced mouse calvarial osteolysis. (A) Representative histological sections stained with hematoxylin and eosin (H&E) and stained for tartrate-resistant acid phosphatase (TRAP). (B) Histomorphometric analysis of the number of TRAP-positive multinucleated osteoclasts in the sections. ** p < 0.01.
Ijms 26 05426 g010
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wang, W.; Wu, C.; Tian, B.; Liu, X.; Zhai, Z.; Qu, X.; Jiang, C.; Ouyang, Z.; Mao, Y.; Tang, T.; et al. Correction: Wang et al. The Inhibition of RANKL-Induced Osteoclastogenesis through the Suppression of p38 Signaling Pathway by Naringenin and Attenuation of Titanium-Particle-Induced Osteolysis. Int. J. Mol. Sci. 2014, 15, 21913–21934. Int. J. Mol. Sci. 2025, 26, 5426. https://doi.org/10.3390/ijms26125426

AMA Style

Wang W, Wu C, Tian B, Liu X, Zhai Z, Qu X, Jiang C, Ouyang Z, Mao Y, Tang T, et al. Correction: Wang et al. The Inhibition of RANKL-Induced Osteoclastogenesis through the Suppression of p38 Signaling Pathway by Naringenin and Attenuation of Titanium-Particle-Induced Osteolysis. Int. J. Mol. Sci. 2014, 15, 21913–21934. International Journal of Molecular Sciences. 2025; 26(12):5426. https://doi.org/10.3390/ijms26125426

Chicago/Turabian Style

Wang, Wengang, Chuanlong Wu, Bo Tian, Xuqiang Liu, Zanjing Zhai, Xinhua Qu, Chuan Jiang, Zhengxiao Ouyang, Yuanqing Mao, Tingting Tang, and et al. 2025. "Correction: Wang et al. The Inhibition of RANKL-Induced Osteoclastogenesis through the Suppression of p38 Signaling Pathway by Naringenin and Attenuation of Titanium-Particle-Induced Osteolysis. Int. J. Mol. Sci. 2014, 15, 21913–21934" International Journal of Molecular Sciences 26, no. 12: 5426. https://doi.org/10.3390/ijms26125426

APA Style

Wang, W., Wu, C., Tian, B., Liu, X., Zhai, Z., Qu, X., Jiang, C., Ouyang, Z., Mao, Y., Tang, T., Qin, A., & Zhu, Z. (2025). Correction: Wang et al. The Inhibition of RANKL-Induced Osteoclastogenesis through the Suppression of p38 Signaling Pathway by Naringenin and Attenuation of Titanium-Particle-Induced Osteolysis. Int. J. Mol. Sci. 2014, 15, 21913–21934. International Journal of Molecular Sciences, 26(12), 5426. https://doi.org/10.3390/ijms26125426

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop